Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1469 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

FDA approves Mylan Fludarabine Phosphate injection ANDA

Mylan claims that its Fludarabine Phosphate injection USP, 25mg/ml is bioequivalent and therapeutically equivalent to Teva Parenteral’s Fludarabine Phosphate injection USP, 25mg/ml. Fludarabine is a chemotherapy drug that

caprotec bioanalytics names new chief operating officer

Berlin, Germany-based caprotec bioanalytics focuses on the commercialisation of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. Prior to joining caprotec, Metternich was the vice president and head

PPD expands presence in Russia

PPD, which already has offices in Moscow, Smolensk and St Petersburg, intends to strengthen its presence in Russia with this new office. PPD is a contract research organisation

Merck to transfer Caeylx marketing rights to Janssen

Caeylx is a long-circulating pegylated liposomal formulation of doxorubicin hydrochloride, a cytotoxic agent. Currently, Merck, through an affiliate, holds rights to market the medication under a distribution agreement

GSK halts Simplirix Phase III trial

The decision was made following receipt of the results of the Herpevac trial for women, a Phase III trial evaluating efficacy of Simplirix, which was conducted collaboratively with